Update shared on 11 Nov 2025
Fair value Decreased 1.61%Narrative Update on Siemens Healthineers
The analyst price target for Siemens Healthineers was reduced by EUR 1 to EUR 61. Analysts cite shifts in market expectations and adjustments to forecast assumptions for this change.
Analyst Commentary
Bullish Takeaways
- Bullish analysts continue to maintain a positive long-term outlook on Siemens Healthineers and reaffirm a Buy rating, despite the slight reduction in the price target.
- The company's fundamentals and business model remain robust, which provides confidence in its ability to execute its growth strategy.
- Valuation remains attractive, even with minor downward adjustments. This suggests the shares offer upside potential from current levels.
- Recent operational performance and the innovation pipeline are seen as drivers of sustainable earnings growth.
Bearish Takeaways
- Bearish analysts express caution due to shifting market expectations, which has led to a reduction in the price target.
- Persistent macroeconomic uncertainties could weigh on execution and short-term growth prospects.
- Forecast assumptions have been adjusted to reflect potential headwinds and this has impacted near-term valuation.
- Slower than expected recovery or delays in business segments may pose risks to the company meeting its targets.
What's in the News
- Siemens Healthineers AG has provided earnings guidance for the first quarter of 2026, anticipating revenue growth below the outlook range of 5% to 6%. The company expects full-year comparable revenue growth to remain within the 5% to 6% range. Ongoing macroeconomic challenges, particularly a strong euro and tariffs, are projected to offset earnings growth. (Key Developments)
- The company is raising its proposed dividend for 2025 by EUR 0.05 per share, bringing the total to EUR 1 per share. (Key Developments)
- Aiforia Technologies and Siemens Healthineers have announced new and expanded partnerships, including a local agreement in Finland and a strategic collaboration to accelerate the adoption of AI-powered diagnostic solutions across Europe. (Key Developments)
- Siemens Healthineers launched the Atellica DT 250 Analyzer, a new benchtop instrument that provides quality drug testing and enhanced workflow efficiency. The analyzer is capable of processing up to 225 test results per hour. (Key Developments)
- Carna Health and Siemens Healthineers entered a strategic agreement to accelerate adoption of AI-enabled chronic kidney disease screening platforms and point-of-care testing systems. The partnership aims to expand access to care in underserved regions. (Key Developments)
Valuation Changes
- Fair Value Estimate has decreased slightly, moving from €58.81 to €57.86.
- The discount rate has risen from 5.88% to 6.18%, indicating an increased risk factor in the valuation model.
- Revenue growth expectations have edged up modestly, changing from 5.41% to 5.48% per year.
- Net profit margin has improved, increasing from 11.58% to 11.76%.
- Future P/E ratio has fallen from 25.27x to 23.18x, reflecting adjusted growth and valuation forecasts.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.